How Does a Mood Stabilizer Work in the Brain?

Mood stabilizers do not flip a single switch in the brain. They act on a surprisingly wide range of molecular targets at once, and no two mood stabilizers share exactly the same profile of effects. Lithium, the oldest and still the most studied, works through at least two major signaling cascades inside nerve cells, while newer agents like valproate and lamotrigine reach some of those same endpoints through different entry points. That layered, multi-target action is part of why these drugs take weeks to reach full effect and why researchers are still mapping the complete picture decades after lithium first entered clinical use.

Lithium’s Two Big Molecular Targets

Lithium is a small ion, roughly the same size as magnesium. That size match turns out to be central to how it works: lithium slips into the binding pockets where magnesium normally sits on certain enzymes, and in doing so it blocks their activity. The most important of these enzymes is glycogen synthase kinase-3, usually called GSK-3. GSK-3 is active in many cell-signaling pathways that regulate mood, stress responses, and neuronal survival. Lithium directly inhibits GSK-3 by competing with magnesium, and it also dials down the enzyme indirectly by activating a separate signaling protein called Akt, which adds a chemical tag to GSK-3 that keeps it switched off.¹ Brain tissue studies in animals have confirmed that therapeutically relevant doses of lithium do push GSK-3 toward its inactive state in the living brain, not just in a test tube.² Multiple classes of mood-stabilizing and antidepressant drugs also regulate GSK-3 signaling, which strengthens the case that this enzyme is a genuine therapeutic target rather than an incidental bystander.³

The second major pathway involves a molecule called myo-inositol. Cells use inositol to build signaling lipids that carry messages from the cell surface to the interior. Lithium blocks an enzyme needed to recycle inositol, so over time the supply inside the cell drops. With less inositol available, certain overactive signaling cascades get quieter. This is the “inositol depletion hypothesis,” which has been studied for over 35 years.⁴ Animal experiments suggest the picture is more nuanced than simple depletion: lithium treatment also causes certain inositol-related signaling molecules to accumulate, and both effects may contribute to the drug’s behavioral impact.⁵ A unified model has been proposed in which the inositol depletion and GSK-3 inhibition pathways are not independent but actually feed into each other, which may explain why both lithium and valproate produce overlapping clinical results despite entering the cell through different doors.⁶

How Anticonvulsant Mood Stabilizers Work Differently

Several drugs originally developed for epilepsy turned out to stabilize mood as well. The most widely used are valproate (often called valproic acid or Depakote), carbamazepine, and lamotrigine. Each works through its own set of mechanisms, though they share some common ground with lithium.

Valproate’s most distinctive action involves rebalancing the brain’s main excitatory and inhibitory chemical messengers. Glutamate is the primary excitatory neurotransmitter, and GABA is the primary inhibitory one. Valproate boosts GABA levels by slowing the proteins that transport GABA away from synapses, while simultaneously helping clear excess glutamate by increasing the quantity of a glutamate-transporting protein in the hippocampus.⁷ The net result is less excitatory signaling and more inhibitory braking. In the prefrontal cortex, valproate also directly dampens spontaneous neuronal firing and strengthens GABA-mediated inhibition while blocking responses to the excitatory signal NMDA.⁸

Lamotrigine approaches the problem from the electrical side. It modulates voltage-gated ion channels that control how easily a neuron fires, making neurons less excitable. On top of that, lamotrigine inhibits glutamate release and may enhance GABAergic neurotransmission, giving it neuroprotective properties.⁹ Clinically, lamotrigine stands out from the other anticonvulsant mood stabilizers because it is particularly effective against the depressive pole of bipolar disorder, while valproate and lithium tend to be strongest against mania. That clinical difference likely reflects the distinct signaling profiles of each drug, even though the mechanisms overlap in places.

Carbamazepine acts primarily on sodium channels and also interacts with adenosine receptors and the cyclic AMP signaling pathway. It shares the GSK-3 inhibition story less clearly: brain tissue studies found that carbamazepine, unlike lithium and valproate, did not increase levels of a key downstream marker of GSK-3 inhibition in the frontal cortex, suggesting its mood-stabilizing effect relies on different routes.²

Atypical Antipsychotics Used as Mood Stabilizers

Since the mid-1990s, several atypical (or “second-generation”) antipsychotics have been recognized as mood stabilizers in their own right. Clozapine was the first, followed by olanzapine, quetiapine, aripiprazole, and risperidone.¹⁰ These drugs work through an entirely different front door than lithium or the anticonvulsants. They interact with a range of serotonin receptors, particularly the 5-HT2A and 5-HT1A subtypes, as well as with dopamine receptors. What makes them “atypical” is that they tend to bind dopamine D2 receptors with low affinity or act as partial agonists rather than fully blocking them, which reduces some of the movement-related side effects seen with older antipsychotics.¹¹ They also influence glutamate regulation, connecting them to some of the same downstream pathways that lithium and valproate affect through different entry points.

The neurotransmitter landscape of bipolar disorder itself helps explain why multiple receptor targets matter. Norepinephrine and dopamine appear to be low during depressive episodes and elevated during mania, while serotonin runs low in depression but is also imbalanced in mania.¹² A drug that can modulate serotonin, dopamine, and glutamate simultaneously has more leverage over these swinging states than one that only touches a single neurotransmitter system.

Quieting Glutamate at the Synapse

A finding that cuts across multiple mood stabilizers is their ability to reduce the number of AMPA receptors sitting on the surface of neurons. AMPA receptors are the workhorses of fast excitatory signaling: when glutamate hits them, the neuron fires. Chronic treatment with lithium or valproate reduces the amount of a key AMPA receptor subunit (GluR1) at the synapse in the hippocampus. The mechanism involves reducing a specific chemical modification on GluR1 that is necessary for the receptor to be inserted into the cell membrane. Without that tag, fewer receptors reach the surface, and excitatory transmission gets dialed down.¹³ Valproate also reduces the surface expression of a second AMPA subunit, GluR2, while lamotrigine, the more “antidepressant-like” mood stabilizer, does not produce the same reduction and may even work in a complementary direction.¹⁴

This matters because excessive glutamate signaling has increasingly been implicated in mood disorders. Research has shifted the focus of novel drug development away from traditional monoamine-based approaches and toward modulators of glutamatergic signaling as a core feature of the illness, not just a side effect of it. The fact that both lithium and valproate converge on AMPA receptor trafficking despite arriving there by different molecular routes suggests that cooling down glutamate at the synapse is a key part of what makes a mood stabilizer a mood stabilizer.

Growing and Protecting Brain Tissue

One of the more striking discoveries about mood stabilizers is that they do not merely dampen overactive signaling; they also encourage the brain to protect and even rebuild itself. Several mood stabilizers boost levels of brain-derived neurotrophic factor (BDNF), a protein that supports the survival, growth, and branching of neurons. Chronic treatment with carbamazepine and lamotrigine significantly increased BDNF levels in the frontal cortex of rats, along with levels of Bcl-2, an anti-cell-death protein that shields neurons from self-destructing during stress.¹⁵ Lithium and valproate trigger similar upregulation of BDNF and Bcl-2 through overlapping survival-signaling pathways, which may explain some of their delayed long-term benefits: the neurotrophic effects need weeks to build up.¹⁶

Brain imaging brings this out of the lab and into living people. In healthy volunteers given lithium, gray matter volume increased in the left and right dorsolateral prefrontal cortex and the left anterior cingulate, regions intimately involved in decision-making and emotional regulation. Total white matter volume also grew.¹⁷ In bipolar patients specifically, those treated with lithium showed larger volumes of the amygdala and hippocampus compared with patients not taking the drug.¹⁸ These are regions that tend to shrink with repeated mood episodes, so the finding suggests lithium may counteract some of the structural damage that accumulates over the course of the illness.

Cooling Inflammation and Oxidative Stress

The idea that mood disorders involve brain inflammation has gained substantial traction over the past decade, and mood stabilizers appear to tap into this process as well. Lithium suppresses the production of pro-inflammatory molecules like interleukin-1β and tumor necrosis factor-α, while enhancing the synthesis of anti-inflammatory signals like interleukin-2 and interleukin-10. It also damps down the expression of cyclooxygenase-2, an enzyme familiar to anyone who has taken an anti-inflammatory painkiller.¹⁹ Valproate similarly reduces inflammatory responses: in neural tissue, it significantly attenuated pro-inflammatory cytokine expression and shifted the activity of microglia, the brain’s resident immune cells, away from their aggressive, inflammation-promoting state.²⁰

Closely related to inflammation is oxidative stress, where reactive molecules damage cell membranes, proteins, and DNA. Chronic treatment with lithium and valproate at therapeutic concentrations inhibited glutamate-induced rises in free calcium inside cortical neurons and reduced lipid peroxidation, protein oxidation, DNA fragmentation, and cell death.²¹ In other words, the drugs act as a buffer against the kind of cellular damage that unchecked excitatory signaling can cause during severe mood episodes.

Resetting Circadian Rhythms

Sleep disruption is one of the hallmarks of bipolar disorder, and accumulating evidence points to the internal body clock itself as a target of mood stabilizers. In mice engineered to have excessive dopamine signaling, behavioral rhythms stretched out, running on a longer-than-normal cycle. Valproate shortened those stretched rhythms back toward normal, both in the animals’ behavior and in the clock gene expression patterns of the brain’s master clock. The same shortening effect appeared in hippocampal cell lines and in skin cells taken from bipolar patients.²² Because dopamine signaling tends to run high during mania and is itself linked to circadian disruption, the ability of a mood stabilizer to counteract dopamine’s clock-stretching effects adds another layer to how these drugs prevent manic episodes from spiraling.

Epigenetic Effects of Valproate

Valproate does something none of the other classic mood stabilizers do as powerfully: it inhibits enzymes called histone deacetylases. Histones are the spool-like proteins that DNA wraps around, and how tightly or loosely the DNA is wound determines which genes get read and which stay silent. By blocking the enzymes that keep the spools wound tight, valproate loosens the packaging and allows certain genes to be expressed more freely.²³ This epigenetic action may contribute to valproate’s effects on BDNF and Bcl-2 production, since both genes respond to chromatin remodeling. It also means valproate has become one of the most widely used pharmacological tools in neuroepigenetic research, a field that studies how experiences and drugs alter gene expression without changing the DNA sequence itself.

Why the Same Drug Doesn’t Work the Same for Everyone

If mood stabilizers acted on just one target, predicting who would respond would be straightforward. But because they touch so many pathways simultaneously, individual genetics play a substantial role in determining who benefits most from a given drug. A large international consortium studied over 2,300 bipolar patients and developed genetic scores based on pathways known to be affected by lithium. Scores related to the acetylcholine, GABA, and mitochondrial pathways were associated with how well a patient responded to lithium treatment. Scores tied to calcium channels, circadian rhythm genes, and GSK-3 signaling also showed associations, though through a somewhat different statistical lens.²⁴ The practical implication is that a patient whose genetic makeup favors strong GSK-3 inhibition effects may respond well to lithium, while someone whose biology is more sensitive to GABA modulation might do better on valproate. Clinicians currently arrive at these distinctions through trial and error over months. Genetic scoring is not yet precise enough to replace that process, but it represents a step toward prescribing the right mood stabilizer first rather than third.

The Monoamine Backdrop

Much of modern psychiatry was built on the idea that mood disorders stem from imbalances in monoamine neurotransmitters like serotonin, norepinephrine, and dopamine. Mood stabilizers do interact with these systems, but they generally do so indirectly. Lithium, for example, modulates serotonin release and receptor sensitivity over time, but that is a downstream consequence of its effects on intracellular signaling cascades rather than its primary point of entry. The same is true of valproate’s effects on dopamine: by opposing dopamine’s circadian effects and regulating glutamate-GABA balance, it influences dopaminergic tone without directly blocking or boosting dopamine receptors. The atypical antipsychotics are the exception, binding serotonin and dopamine receptors directly, which is why they tend to work faster during acute manic episodes than lithium or valproate do. Understanding that mood stabilizers mostly work downstream of the traditional monoamine story helps explain why they are often combined with antidepressants that act upstream on serotonin, with each class covering a different part of the signaling chain.¹²